Huai Lue An
Director/Board Member chez Guizhou Kekai Pharmaceutical Co., Ltd.
Fortune : 52 M $ au 31/03/2024
Profil
Huai Lue An is currently a Director at Guizhou Kekai Pharmaceutical Co., Ltd.
Previously, he worked as a Chairman at Guizhou Xinbang Pharmaceutical Co., Ltd.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/09/2023 | 98 057 908 ( 86,31% ) | 52 M $ | 31/03/2024 | |
| 10/07/2023 | 670 ( 0,00% ) | 353 $ | 31/03/2024 |
Postes actifs de Huai Lue An
| Sociétés | Poste | Début |
|---|---|---|
Guizhou Kekai Pharmaceutical Co., Ltd.
 Guizhou Kekai Pharmaceutical Co., Ltd. Medical DistributorsDistribution Services Part of Guizhou Xinbang Pharmaceutical Co., Ltd., Guizhou Kekai Pharmaceutical Co., Ltd. is a Chinese company that wholesales pharmaceutical products. The private company is based in Guiyang, China. The company was founded in 1995. Xue Feng Gu has been the CEO of the company since 2016. Guizhou Kekai Pharmaceutical Co. was acquired by Guizhou Xinbang Pharmaceutical Co., Ltd. on March 14, 2014 for $456.24 million. | Director/Board Member | - |
Anciens postes connus de Huai Lue An
| Sociétés | Poste | Fin |
|---|---|---|
| GUIZHOU XINBANG PHARMACEUTICAL CO., LTD. | Chairman | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GUIZHOU XINBANG PHARMACEUTICAL CO., LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Guizhou Kekai Pharmaceutical Co., Ltd.
Guizhou Kekai Pharmaceutical Co., Ltd. Medical DistributorsDistribution Services Part of Guizhou Xinbang Pharmaceutical Co., Ltd., Guizhou Kekai Pharmaceutical Co., Ltd. is a Chinese company that wholesales pharmaceutical products. The private company is based in Guiyang, China. The company was founded in 1995. Xue Feng Gu has been the CEO of the company since 2016. Guizhou Kekai Pharmaceutical Co. was acquired by Guizhou Xinbang Pharmaceutical Co., Ltd. on March 14, 2014 for $456.24 million. | Distribution Services |
